20. A pharmaceutical formulation according to claim 16, wherein the hydrophilic component comprises hydroxypropyl methylcellulose of low viscosity.

21. A pharmaceutical formulation according to claim 19, wherein the hydroxypropyl methylcellulose has a viscosity of about 15 cP.

22. A pharmaceutical formulation according to claim 17, wherein the surfactant comprises sodium docusate.

23. A pharmaceutical formulation according to claim 18, wherein the pH modulator comprises a phosphate buffer.

24. A pharmaceutical formulation according to claim 16, characterized in that it is in the form of a tablet.

25. A pharmaceutical formulation according to claim 23, characterized in that the tablet is lacquered.

26. A pharmaceutical formulation according to claim 23, characterized in that on the tablet an acid-resistant coating is applied.

27. A process for the preparation of a pharmaceutical formulation for peroral single daily application comprising clarithromycin or a derivative thereof and a mixture of a fatty and a hydrophilic component, which comprises forming a homogeneous mixture thereof and direct compressing said mixture into tablet form without use of solvents.

28. A process according to claim 27 comprising sieving the homogeneous mixture prior to compressing the mixture into tablet form.

Examination and allowance of the above claims are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: _____
T. Gene Dillahunty
Registration No. 25,423

P.O. Box 1404
Alexandria, Virginia 22313-1404
(650)622-2300

Date: August 17, 2001